| Differentiation induction therapy of myelodysplastic syndromes. | |
| | |
MedLine Citation:
|
PMID: 2668648 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Myelodysplastic syndromes are a heterogenous group of haemopoietic stem cell disorders characterized by dysplastic haematopoiesis and a defective maturation of a slowly expanding or sometimes of a stable population of haemopoietic progenitors. Defective maturation, which may involve one or more of the marrow cell lineages is regarded as the central pathophysiological feature of myelodysplastic syndromes. Patients with myelodysplastic syndromes respond poorly to conventional cytotoxic chemotherapy, frequently developing a prolonged marrow aplasia. The alternative and more appropriate form of therapy is differentiation induction therapy. The results of few preliminary clinical studies in myelodysplastic patients showed that a combination of differentiating agents is superior to single agent differentiation therapy. An extensive pre-clinical screening of the response of fresh cells from myelodysplastic patients in primary culture is needed to establish the optimal doses and conditions for significant synergies between various differentiating agents followed by large controlled randomized clinical trials based on differentiation induction therapy for patients with myelodysplastic syndromes. |
| | |
Authors:
|
H T Hassan; J Rees |
Related Documents
:
|
20430198 - The risk factors for cytomegalovirus syndrome and tissue-invasive cytomegalovirus disea... 21817958 - Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovasculari... 19490778 - Tese-icsi in patients with non-mosaic klinefelter syndrome: a comparative study. 21333908 - Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, prob... 21723458 - Intracranial artery dissection in an adolescent with marfan syndrome. 2319578 - Yunis-varon syndrome with severe osteodysplasty. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Leukemia research Volume: 13 ISSN: 0145-2126 ISO Abbreviation: Leuk. Res. Publication Date: 1989 |
Date Detail:
|
Created Date: 1989-09-19 Completed Date: 1989-09-19 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7706787 Medline TA: Leuk Res Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 633-7 Citation Subset: IM |
Affiliation:
|
Department of Haematological Medicine, University of Cambridge Clinical School, England, U.K. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cell Differentiation
/
drug effects* Humans Myelodysplastic Syndromes / drug therapy, pathology* Neoplastic Stem Cells / pathology* |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment of RAEB-t with intensive chemotherapy and GM-CSF.
Next Document: Comprehensive polypeptide analysis of microdissected rat brain areas: combining 2-dimensional gel el...